1

Cumberland Pharmaceuticals

Cumberland Pharmaceuticals
Leadership team

Mr. A. J. Kazimi MBA (Founder, Chairman, Pres & CEO)

Mr. John Michael Hamm (Sr. Director of Fin. & Accounting and CFO)

Mr. James Lowrance Herman (Exec. VP of National Accounts & Chief Compliance Officer)

Products/ Services
Biotechnology, Health Care
Number of Employees
50 - 100
Headquarters
Nashville, Tennessee, United States
Established
1999
Company Registration
SEC CIK number: 0001087294
Revenue
20M - 100M
Traded as
NASDAQ:CPIX
Social Media
Overview
Location
Summary
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.
History

Cumberland Pharmaceuticals was founded in 2003 and has since grown to become a leader in specialty pharmaceuticals

Mission
To provide innovative, high-quality healthcare products that improve patient lives and caregivers experience.
Vision
To be the most trusted specialty pharmaceuticals company in the industry, serving patients and healthcare providers with best-in-class products and services.
Key Team

Ms. Jean W. Marstiller (Sr. VP of Admin. Services & Corp. Sec.)

Mr. Adam S. Mostafa (Managing Director)

Ms. Cindy B. Patton (Sr. Director of Field Marketing)

Mr. Todd M. Anthony (VP of Organizational Devel.)

Ms. Erin Smith Gull (Sr. Corp. Relations Associate)

Recognition and Awards
Recognized as Pharmaceutical Innovator of the Year for three consecutive years.
References

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Cumberland Pharmaceuticals
Leadership team

Mr. A. J. Kazimi MBA (Founder, Chairman, Pres & CEO)

Mr. John Michael Hamm (Sr. Director of Fin. & Accounting and CFO)

Mr. James Lowrance Herman (Exec. VP of National Accounts & Chief Compliance Officer)

Products/ Services
Biotechnology, Health Care
Number of Employees
50 - 100
Headquarters
Nashville, Tennessee, United States
Established
1999
Company Registration
SEC CIK number: 0001087294
Revenue
20M - 100M
Traded as
NASDAQ:CPIX
Social Media